Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Solid Biosciences

Solid Biosciences (NASDAQ: SLDB) insider transactions

In the twelve months to 10 November 2026, executives and directors of Solid Biosciences reported 27 open-market sales of 425,821 shares ($2.7m) and 0 open-market purchases, by 7 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Solid Biosciences shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
19 October 2026Brooks GabrielChief Medical OfficerOpen-market sale, 10b5-1 plan−4,374$5.6297,241Form 4
18 October 2026Brooks GabrielChief Medical OfficerOption exercise, 10b5-1 plan+9,750—101,615Form 4
2 October 2026Smith Ian FDirectorOption exercise+3,440—141,585Form 4
2 July 2026Smith Ian FDirectorOption exercise+3,440—138,145Form 4
2 April 2026Smith Ian FDirectorOption exercise+3,441—134,705Form 4
18 February 2026Tan KevinCFO & TreasurerOpen-market sale−5,404$5.8299,422Form 4
18 February 2026Howton David TChief Operating OfficerOpen-market sale−7,469$5.82105,077Form 4
18 February 2026Herzich PaulChief Technology OfficerOpen-market sale−3,616$5.8272,638Form 4
18 February 2026Ganot IlanDirectorOpen-market sale−2,658$5.8227,474Form 4
18 February 2026Hanrahan JessieChief Regulatory OfficerOpen-market sale−4,134$5.8274,318Form 4
18 February 2026Cumbo AlexanderPresident and CEOOpen-market sale−16,644$5.82235,405Form 4
13 February 2026Tan KevinCFO & TreasurerOption exercise+10,625—104,826Form 4
13 February 2026Brooks GabrielChief Medical OfficerOption exercise+10,937—95,029Form 4
13 February 2026Howton David TChief Operating OfficerOption exercise+14,687—112,546Form 4
13 February 2026Herzich PaulChief Technology OfficerOption exercise+7,187—76,254Form 4
13 February 2026Ganot IlanDirectorOption exercise+4,861—30,132Form 4
13 February 2026Hanrahan JessieChief Regulatory OfficerOption exercise+8,125—78,452Form 4
13 February 2026Cumbo AlexanderPresident and CEOOption exercise+30,031—252,049Form 4
4 February 2026Herzich PaulChief Technology OfficerOpen-market sale−10,905$6.4469,067Form 4
4 February 2026Hanrahan JessieChief Regulatory OfficerOpen-market sale−12,348$6.4470,327Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Solid Biosciences page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.